Regulatory Spine DiscGenics Announces US FDA Approval to Proceed with Phase III Clinical Evaluation of Allogeneic, Injectable Disc Progenitor Cell Therapy for Symptomatic Lumbar Degenerative Disc Disease byTim AllenJuly 16, 2024
Biologics Spine Top Stories DiscGenics Announces the International Journal of Spine Surgery Has Published Results from an FDA-Approved Study of an Allogeneic Disc Progenitor Cell Therapy for the Treatment of Adults with Lumbar Disc Degeneration byJosh SandbergJuly 9, 2024
Biologics Spine DiscGenics Announces Research Collaboration with the U.S. Department of Veterans Affairs for Tissue-Engineered Discs with Discogenic Cells byJosh SandbergOctober 18, 2023
Spine Top Stories DiscGenics Announces Positive Two-Year Clinical Data from Study of Discogenic Progenitor Cell Therapy for Degenerative Disc Disease byJosh SandbergJanuary 23, 2023
Biologics Spine DiscGenics to Present at 2022 Cell & Gene Meeting on the Mesa byChris StewartOctober 5, 2022
Spine Top Stories DiscGenics Announces Presentation of Positive Interim Clinical Data from Phase 1/2 Study of Cell Therapy for Degenerative Disc Disease byJosh SandbergFebruary 25, 2022
Biologics Spine DiscGenics Completes Patient Enrollment in Japanese Clinical Study of Cell Therapy for Disc Degeneration as US Study Achieves One-Year Follow-up Milestone byJosh SandbergApril 27, 2021
Biologics Spine DiscGenics Announces Completion of Enrollment in U.S. Phase 1/2 Clinical Trial of Discogenic Cell Therapy for Degenerative Disc Disease byChris StewartMarch 4, 2020
Biologics Spine DiscGenics’ U.S. Clinical Study of Cell Therapy for Disc Degeneration Passes Halfway Mark byChris StewartSeptember 16, 2019
